Galapagos, GSK successfully conclude phase 2a study of skin disease drug

Send a link to a friend  Share

[April 17, 2014]  BRUSSELS (Reuters) Belgian biotech group Galapagos NV on Thursday said it has successfully concluded the phase 2a study of a skin disease drug it is developing with Britain's GlaxoSmithKline PLC.

Galapagos tested drug GSK2586184 on 66 patients with chronic psoriasis and observed a 75 percent improvement in significantly more patients than in the placebo group.

GSK, which owns the drug's commercial rights, will decide whether to proceed with clinical trials, Galapagos said in a statement.

Galapagos said it could receive a milestone payment of up to 34 million euros ($46.94 million) as well as double-digit royalties as the program proceeds towards commercialization.

($1 = 0.7243 euros)

(Reporting by Robert-Jan Bartunek; editing by Christopher Cushing)

[ 2014 Thomson Reuters. All rights reserved.]

Copyright 2014 Reuters. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.


< Recent articles

Back to top